PRO DEX INC PDEX
"Pro-Dex," "we," "our," "us") specializes in the design, development, and manufacture
of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic,
and craniomaxillofacial ("CMF") markets. We have patented adaptive torque-limiting technology and proprietary sealing
solutions that appeal to our customers, primarily medical device distributors. Additionally, we provide engineering, quality and regulatory
Last close
73.41
2026-09-04
Market cap
$235.2M
2026-06-30 share count
52-week range
23.47 - 77.00
Valuation FY2026 figures against the last close
P/S3.0x
P/E17.8x
P/FCF34.8x
EV/EBITDA16.9x
Dividend yield—
Diluted EPS4.12
Annual financial statements
Income statement
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $77.5M | $66.6M | $53.8M | $46.1M | $42.0M | $38.0M | $34.8M | $27.2M | $22.5M | $21.9M |
| Cost of revenue | $53.2M | $47.1M | $39.3M | $33.3M | $28.9M | $24.5M | $21.7M | $17.4M | $14.5M | $14.8M |
| Gross profit | $24.3M | $19.5M | $14.6M | $12.7M | $13.1M | $13.6M | $13.1M | $9.8M | $7.9M | $7.2M |
| R&D | $3.3M | $3.6M | $3.2M | $2.8M | $3.0M | $4.4M | $2.3M | $1.9M | $1.9M | $1.2M |
| SG&A | $8.0M | $5.2M | $4.1M | $4.0M | $4.9M | $4.1M | $3.2M | $2.5M | $2.3M | $2.5M |
| Total operating expenses | $11.3M | $8.8M | $7.4M | $7.0M | $8.0M | $9.1M | $6.1M | $4.8M | $5.6M | $4.4M |
| Operating income | $13.0M | $10.7M | $7.2M | $5.8M | $5.1M | $4.5M | $7.1M | $5.0M | $2.4M | $2.7M |
| Interest expense | $812.0K | $829.0K | $558.0K | $533.0K | $464.0K | $352.0K | $236.0K | $220.0K | $7.0K | $12.0K |
| Pre-tax income | $18.0M | $12.1M | $2.6M | $9.4M | $5.7M | $7.6M | $7.9M | $5.4M | $2.6M | $2.8M |
| Income tax | $4.4M | $3.1M | $507.0K | $2.4M | $1.1M | $1.4M | $1.8M | $1.3M | $989.0K | $2.1M |
| Net income | $13.7M | $9.0M | $2.1M | $7.1M | $4.6M | $6.2M | $6.1M | $4.1M | $1.6M | $5.1M |
| EPS, basic | 4.24 | 2.73 | 0.61 | 1.98 | 1.26 | 1.63 | 1.56 | 0.99 | 0.38 | 1.26 |
| EPS, diluted | 4.12 | 2.67 | 0.60 | 1.95 | 1.21 | 1.57 | 1.50 | 0.97 | 0.37 | 1.25 |
| Shares, diluted (wtd. avg.) | $3.3M | $3.4M | $3.6M | $3.6M | $3.8M | $3.9M | $4.1M | $4.3M | $4.3M | $4.1M |
Balance sheet
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.2M | $419.0K | $2.6M | $2.9M | $849.0K | $3.7M | $6.4M | $7.7M | $5.2M | $4.2M |
| Short-term investments | $1.1M | $6.7M | $4.2M | $1.1M | $755.0K | $1.3M | $2.6M | $1.7M | $2.2M | $718.0K |
| Receivables | $21.2M | $16.4M | $13.9M | $10.0M | $15.4M | $10.9M | $5.2M | $4.1M | $3.0M | $3.5M |
| Inventory | $21.5M | $22.2M | $15.3M | $16.2M | $12.7M | $8.4M | $8.2M | $6.2M | $4.4M | $3.1M |
| Total current assets | $53.2M | $47.3M | $36.6M | $31.0M | $31.2M | $25.0M | $22.7M | $20.8M | $16.2M | $12.3M |
| Property, plant and equipment | $5.4M | $5.2M | $5.0M | $5.1M | $4.8M | $3.8M | $2.7M | $2.7M | $1.8M | $1.4M |
| Goodwill | $6.5M | — | — | — | — | — | — | — | — | $112.0K |
| Other intangibles | $686.0K | $26.0K | $54.0K | $81.0K | $118.0K | $186.0K | $162.0K | $129.0K | $140.0K | $149.0K |
| Total assets | $74.5M | $61.2M | $52.5M | $51.8M | $49.1M | $42.9M | $31.5M | $25.5M | $19.9M | $16.4M |
| Accounts payable | $4.3M | $4.6M | $4.5M | $2.3M | $3.8M | $2.3M | $2.0M | $2.0M | $1.1M | $1.2M |
| Total current liabilities | $13.0M | $14.6M | $12.9M | $9.7M | $11.4M | $6.3M | $5.2M | $4.3M | $2.4M | $2.6M |
| Long-term debt | $17.5M | $15.4M | $12.0M | $12.8M | $13.6M | $12.8M | $4.0M | $4.6M | — | — |
| Total liabilities | $26.9M | $24.6M | $21.6M | $20.2M | $23.7M | $20.2M | $12.1M | $3.3M | $2.6M | $2.6M |
| Retained earnings | $47.6M | $35.9M | $26.9M | $24.8M | $17.7M | $14.3M | $8.1M | $1.7M | -$2.4M | -$4.0M |
| Total equity | $47.6M | $36.6M | $30.9M | $31.6M | $25.4M | $21.1M | $19.1M | $17.0M | $17.3M | $13.7M |
Cash flow
| Fiscal year | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $7.2M | -$1.7M | $6.2M | $5.5M | -$847.0K | -$2.1M | $4.9M | $3.3M | $3.1M | $3.2M |
| Depreciation and amortisation | $1.4M | $1.2M | $1.2M | $857.0K | $726.0K | $686.0K | $573.0K | $438.0K | $557.0K | $555.0K |
| Stock-based compensation | $688.0K | $555.0K | $605.0K | $766.0K | $1.3M | $901.0K | $286.0K | $37.0K | $194.0K | $3.0K |
| Capital expenditure | $483.0K | $1.2M | — | — | $1.6M | $1.8M | $519.0K | $1.4M | $923.0K | $606.0K |
| Investing cash flow | $3.9M | -$238.0K | -$2.2M | -$885.0K | -$1.2M | -$3.7M | -$2.3M | -$1.2M | -$4.1M | -$1.0M |
| Financing cash flow | -$3.4M | -$292.0K | -$4.3M | -$2.5M | -$790.0K | $3.1M | -$4.0M | $450.0K | $2.0M | -$298.0K |
| Buybacks | $3.4M | $3.5M | $3.5M | $1.5M | $1.6M | $5.5M | $3.4M | $4.0M | $220.0K | $312.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001079973-26-001215.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |